The Vaccine protected the young women completely against precancerous Lesions (medium - or high-grad) of the Cervix related to HPV 16 and 18. The protection result was 100 % of cases! The sid-effects comes with an extremely low number. If we see the large number of cases in this study, the results should be the same if vaccination is made Available to the public.
Cervical Cancer is the second leading cancer in Young women and accounts for 11 % of Cancers in all women! When the Women has a common genital Infection with the human papillomavirus (HPV) and its can result in the appearance of precancerous lesions of the Cervix Mucous membrane. For instance, we know that the connection between HPV infection and cervical cancer is much stronger than that between smoking and lung cancer.
The most oncogenic subtypes of HPV can now be wiped out thanks to this new quadrivalent vaccine. The first step is vaccinating adolescents (D3 - “Chronical”) before they come into contact with the virus; this is a turning point in the fight against cancer. It is a major tool in the prevention of precancerous lesions in the cervix. No virus, no lesions - and if there are no lesions, that means no cancer. Prevention is an essential part of the equation when it comes to combating cervical cancer - that's why oncologists are so excited about the new Vaccine.
A study conducted with more than 20,000 women has shown the absolute effectiveness of a vaccine in the prevention of cervical cancer due to the most common types of human papillomavirus (HPV). Oncologists are enthusiastic. It is a rare thing to hear physicians - and even more so, oncologists -get excited to the point of speaking of a “historical breakthrough” after hearing a presentation from a colleague.
